LUC00157I2 - - Google Patents

Download PDF

Info

Publication number
LUC00157I2
LUC00157I2 LU00157C LUC00157C LUC00157I2 LU C00157 I2 LUC00157 I2 LU C00157I2 LU 00157 C LU00157 C LU 00157C LU C00157 C LUC00157 C LU C00157C LU C00157 I2 LUC00157 I2 LU C00157I2
Authority
LU
Luxembourg
Application number
LU00157C
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36917059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00157(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Publication of LUC00157I1 publication Critical patent/LUC00157I1/fr
Publication of LUC00157I2 publication Critical patent/LUC00157I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU00157C 2005-02-16 2020-06-08 LUC00157I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65406005P 2005-02-16 2005-02-16
EP06735282.3A EP1853251B1 (fr) 2005-02-16 2006-02-16 Boronophthalides substitues par halogene pour le traitement d'infections

Publications (2)

Publication Number Publication Date
LUC00157I1 LUC00157I1 (fr) 2020-06-08
LUC00157I2 true LUC00157I2 (fr) 2021-07-06

Family

ID=36917059

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00157C LUC00157I2 (fr) 2005-02-16 2020-06-08

Country Status (26)

Country Link
US (11) US7582621B2 (fr)
EP (4) EP1853251B1 (fr)
JP (6) JP5038912B2 (fr)
KR (4) KR101337045B1 (fr)
CN (2) CN101160124A (fr)
AU (3) AU2006214247C1 (fr)
BR (1) BRPI0608431B8 (fr)
CA (1) CA2597982C (fr)
CY (3) CY1120695T1 (fr)
DK (3) DK2987796T3 (fr)
ES (4) ES2540966T3 (fr)
FR (1) FR20C1024I2 (fr)
HK (3) HK1160139A1 (fr)
HU (4) HUE026021T2 (fr)
IL (2) IL185080A (fr)
LT (1) LTC2343304I2 (fr)
LU (1) LUC00157I2 (fr)
MX (1) MX369262B (fr)
NL (1) NL301049I2 (fr)
NZ (3) NZ578297A (fr)
PL (4) PL1853251T3 (fr)
PT (4) PT2343304E (fr)
RU (3) RU2414906C2 (fr)
SI (3) SI3424932T1 (fr)
WO (1) WO2006089067A2 (fr)
ZA (4) ZA200707408B (fr)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820186B2 (en) 2001-12-21 2010-10-26 Galderma Research & Development Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
ES2540966T3 (es) * 2005-02-16 2015-07-15 Anacor Pharmaceuticals, Inc. Compuestos biocidas de boronoftalida
US7793666B2 (en) * 2005-07-28 2010-09-14 Innovation Biomedical Devices, Inc. Apparatus and method for treatment of infected nail
BRPI0621279B1 (pt) 2005-12-30 2021-07-20 Anacor Pharmaceuticals, Inc Moléculas pequenas contendo boro
DK2719388T3 (da) 2006-02-16 2019-05-13 Anacor Pharmaceuticals Inc Borholdige små molekyler som antiinflammatoriske midler
US8106031B2 (en) * 2006-05-02 2012-01-31 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
EP1900378A1 (fr) * 2006-08-31 2008-03-19 Novartis AG Compositions pharmaceutiques pour le traitment d'infections fongiques
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
FR2910320B1 (fr) * 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
JP2015178508A (ja) * 2008-01-09 2015-10-08 アナコール ファーマシューティカルズ，インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
EP3246034A1 (fr) 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore en tant qu'agents anti-inflammatoires
EP2187893A4 (fr) * 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc Petites molécules contenant du bore utilisées en tant qu'agents anti-inflammatoires
EP2282742A1 (fr) * 2008-04-09 2011-02-16 Infinity Pharmaceuticals, Inc. Inhibiteurs d'hydrolase d'amide d'acide gras
EP2285384A4 (fr) * 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc Petites molécules contenant du bore
WO2010011354A2 (fr) * 2008-07-25 2010-01-28 Innovation Biomedical Devices, Inc. Administration de médicament de trans-kératine améliorée
WO2010027975A1 (fr) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US9493489B2 (en) 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
JP2012512262A (ja) 2008-12-17 2012-05-31 アナコール ファーマシューティカルズ，インコーポレーテッド （ｓ）−３−アミノメチル−７−（３−ヒドロキシ−プロポキシ）−３ｈ−ベンゾ［ｃ］［１，２］オキサボロール−１−オールの多形体
WO2010118155A1 (fr) * 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibiteurs d'amide d'hydrolase d'acide gras
CA2757622A1 (fr) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibiteurs d'hydrolase d'amide d'acide gras
US8343944B2 (en) 2009-07-28 2013-01-01 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
WO2011019612A1 (fr) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore en tant qu'agents antiprotozoaires
WO2011019616A1 (fr) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore à titre d'agents anti-protozoaires
WO2011019618A1 (fr) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore et utilisables en tant qu'agents antiprotozoaires
MX2012002031A (es) * 2009-08-19 2012-07-04 Anacor Pharmaceuticals Inc Moleculas pequeñas que contienen boro como agentes antiprotozoarios.
WO2011037731A1 (fr) 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
US8979820B2 (en) 2009-10-09 2015-03-17 Cynthia S. Bailey Method and apparatus for improving the appearance of nails affected by onychomycosis through the topical application of an aqueous solution containing boric acid and camphor or other terpenes
WO2011049971A1 (fr) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore comme agents antiprotozoaires
WO2011060199A1 (fr) 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Petites molecules contenant du bore
WO2011063293A1 (fr) 2009-11-20 2011-05-26 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore en tant qu'agents antihelminthes
WO2011094450A1 (fr) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Petites molecules contenant du bore
MX336742B (es) 2010-02-03 2016-01-29 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso.
WO2011116348A1 (fr) 2010-03-19 2011-09-22 Anacor Pharmaceuticals, Inc. Petites molécules borées en tant qu'agent anti-protozoaire
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
PL2603514T3 (pl) 2010-08-10 2019-04-30 Rempex Pharmaceuticals Inc Cykliczne pochodne estrowe kwasu boronowego oraz ich zastosowania terapeutyczne
DK2613788T3 (en) 2010-09-07 2017-08-07 Anacor Pharmaceuticals Inc BENZOXABOROLD DERIVATIVES FOR TREATMENT OF BACTERIA INFECTIONS
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013049424A1 (fr) 2011-09-28 2013-04-04 Wisconsin Alumni Research Foundation Conversion catalytique de la cellulose en carburants et en produits chimiques avec des acides boroniques
AU2012320382B2 (en) * 2011-10-07 2015-11-26 Syngenta Participations Ag Method for protecting useful plants or plant propagation material
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
AR088668A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014007831A1 (fr) 2012-07-06 2014-01-09 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894892A1 (fr) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Derives d'acide boronique et leurs utilisations therapeutiques
CN104994844A (zh) 2013-01-04 2015-10-21 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US8669207B1 (en) * 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
CA2899317A1 (fr) * 2013-01-30 2014-08-07 Dow Agrosciences Llc Utilisation des benzoxaboroles a titre d'agents antimicrobiens volatils sur les viandes, les plantes, ou des parties de plantes
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9598443B2 (en) 2013-02-01 2017-03-21 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
AR094961A1 (es) 2013-03-15 2015-09-09 Lilly Co Eli 1-hidroxi-benzooxaboroles como agentes antiparasitarios
AU2014202928B1 (en) * 2013-06-05 2014-09-11 Agrofresh Inc. Compounds and compositions
CN104224810B (zh) * 2013-06-20 2017-04-19 中国科学院上海生命科学研究院 一种化合物及其衍生物治疗肺炎球菌感染性疾病的用途
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
LT3030519T (lt) * 2013-08-09 2022-04-11 Glaxosmithkline Intellectual Property (No. 2) Limited Tricikliniai benzoksaborolo junginiai ir jų naudojimas
AU2014329421B2 (en) 2013-10-03 2018-08-02 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
EP3071295A4 (fr) 2013-11-22 2017-05-31 Dow Pharmaceutical Sciences, Inc. Procédés, compositions et dispositifs anti-infectieux
MX2016010451A (es) * 2014-02-17 2016-09-22 Syngenta Participations Ag Benzoxaboroles microbicidamente activos.
US10065029B2 (en) 2014-03-03 2018-09-04 Cook Medical Technologies Llc Mechanical dilator
EP3139930B1 (fr) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Sels et polymorphes de dérivés cycliques d'ester d'acide boronique, et leurs utilisations thérapeutiques
PT3140310T (pt) 2014-05-05 2019-11-18 Rempex Pharmaceuticals Inc Síntese de sais de boronato e utilizações dos mesmos
JP2015212249A (ja) * 2014-05-05 2015-11-26 アナコール ファーマシューティカルズ，インコーポレイテッド 化合物および爪光沢剤
JP6682454B2 (ja) * 2014-05-12 2020-04-15 アグロフレッシュ インコーポレイテッド 病原体に対する揮発適用
CA2947041A1 (fr) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Derives d'acide boronique et leurs utilisations therapeutiques
CN106536529B (zh) 2014-07-01 2019-09-27 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
CA2953881A1 (fr) 2014-07-01 2016-01-07 Daiichi Sankyo Company, Limited Benzoxaboroles tricycliques en tant qu'agents antibacteriens
SG11201703184SA (en) 2014-10-21 2017-05-30 Hexima Ltd A method of treatment
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
MA41494B1 (fr) 2015-02-12 2020-10-28 Glaxosmithkline Ip No 2 Ltd Composés benzoxaborole substitués en position 4 et utilisations associées
WO2016149393A1 (fr) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Dérivés d'acide boronique et leurs utilisations thérapeutiques
KR101580077B1 (ko) * 2015-03-28 2015-12-24 한국콜마주식회사 시크로피록스 함유 네일락카 조성물
BR112017021478B1 (pt) * 2015-04-09 2022-04-19 The Penn State Research Foundation Composição antifúngica sinérgica que contém benzoxaborol
US10011616B2 (en) 2015-04-09 2018-07-03 Mmv Medicines For Malaria Venture Boron-containing small molecules as antiprotozoal1 agents
WO2016201440A1 (fr) * 2015-06-12 2016-12-15 The Regents Of The University Of California Spiro-indolinones et leurs utilisations thérapeutiques
CA3014757C (fr) * 2015-08-06 2020-01-14 The Penn State Research Foundation Revetement contenant du benzoxaborole resistant a un champignon susceptible d'etre porte par la cellulose
CN106467557B (zh) * 2015-08-18 2019-05-03 北京海美桐医药科技有限公司 他瓦硼罗的一种制备方法
EP3383363B1 (fr) 2015-11-30 2021-01-06 Anacor Pharmaceuticals, Inc. Formulations pharmaceutiques topiques pour le traitement d'états inflammatoires
US10874679B2 (en) 2016-03-02 2020-12-29 Bill & Melinda Gates Foundation Boron-containing small molecules
US10611780B2 (en) 2016-03-02 2020-04-07 Bill And Melinda Gates Foundation Boron-containing small molecules
EP3423159A4 (fr) * 2016-03-02 2019-11-06 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
WO2017155877A1 (fr) 2016-03-07 2017-09-14 Agrofresh Inc. Administration vaporisée de pesticides
EP3426029B1 (fr) 2016-03-07 2023-08-30 AgroFresh Inc. Procédés synergiques d'utilisation de composés de benzoxaborole et de gaz de conservation en tant qu'agent antimicrobien pour les plantes cultivées
BR112018073017B1 (pt) * 2016-05-09 2022-06-14 Anacor Pharmaceuticals, Inc Forma cristalina i de crisaborol na forma livre, método de preparação e uso da mesma
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
US10294249B2 (en) 2016-06-30 2019-05-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US20170305936A1 (en) 2016-07-12 2017-10-26 Pliva Hrvatska D.O.O. Solid state forms of crisaborole
US10743232B1 (en) 2016-11-15 2020-08-11 Sprint Spectrum L.P. Controlling handover based on carrier-aggregation policies and UE capabilities
WO2018115362A1 (fr) 2016-12-22 2018-06-28 Laboratorios Lesvi, Sl Procédé de préparation de 4-[(1-hydroxy-1,3-dihydro -2,1-benzoxaborol-5-yl)oxy]benzonitrile (crisaborole)
GB201701583D0 (en) * 2017-01-31 2017-03-15 Drug Delivery Solutions Ltd Topical composition
WO2018150327A1 (fr) * 2017-02-14 2018-08-23 Wavelength Enterprises Ltd Procédé de production de crisaborole
US10973835B2 (en) 2017-03-09 2021-04-13 The Penn State Research Foundation Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase
WO2018207216A1 (fr) 2017-05-12 2018-11-15 Biophore India Pharmaceuticals Pvt. Ltd. Procédé de préparation de 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile (crisaborole)
US10865217B2 (en) 2017-05-23 2020-12-15 Msn Laboratories Private Limited, R & D Center Process for the preparation of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and polymorphs thereof
CA3078627A1 (fr) 2017-10-11 2019-04-18 Qpex Biopharma, Inc. Derives d'acide boronique et synthese de ces derniers
EP3704100B1 (fr) 2017-11-02 2023-08-30 Halcyon Labs Private Limited Nouveau procédé de préparation de tavaborole et de ses intermédiaires
BR112020010927A2 (pt) 2017-11-30 2020-12-01 Boragen, Inc. compostos de benzoxaborol e formulações dos mesmos
US10329311B1 (en) 2017-12-21 2019-06-25 Olon S.P.A. Process for the preparation of crisaborole
CN108148085B (zh) 2018-01-04 2019-11-01 合肥医工医药股份有限公司 具有抑制磷酸二酯酶4的化合物、制法及其药物用途
US11014944B2 (en) 2018-01-09 2021-05-25 Halcyon Labs Private Limited Process for the preparation of crisaborole and its intermediates
US10597410B2 (en) 2018-02-02 2020-03-24 Dipharma Francis S.R.L. Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent
CN108451898A (zh) * 2018-04-03 2018-08-28 苏州尚宜佳生物科技有限公司 一种克立硼罗温敏凝胶剂及其制备方法和应用
JP7329260B2 (ja) 2018-04-20 2023-08-18 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
GB201809378D0 (en) * 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
CN108659024A (zh) * 2018-07-24 2018-10-16 武汉轻工大学 克立硼罗的制备方法
JP7268132B2 (ja) * 2018-07-31 2023-05-02 エムシー２・セラピューティクス・リミテッド 局所用組成物
JP2021534247A (ja) 2018-08-18 2021-12-09 ボラゲン，インコーポレーテッド 置換ベンゾキサボロールの固体形態およびその組成物
SG11202102674RA (en) 2018-10-05 2021-04-29 Pfizer Boron containing pde4 inhibitors
EP3941449A1 (fr) 2019-03-20 2022-01-26 Rita Dobmeyer Composition pharmaceutique
US12065456B2 (en) * 2019-07-25 2024-08-20 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Boron-containing pharmacophore
CN110664756B (zh) * 2019-10-09 2020-11-17 吉林大学 一种小儿外伤喷雾剂及其制备方法
US20230340530A1 (en) 2020-08-31 2023-10-26 Pfizer Inc. Methods of Protecting RNA
CN114644645B (zh) * 2022-03-08 2023-05-26 南京农业大学 3-吲哚取代苯硼唑类化合物及其制备方法和应用
CA3239096A1 (fr) * 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Procedes et utilisations de composes de bore dans le traitement d'infections par mycobacteries non tuberculeuses et compositions pharmaceutiques pour le traitement de celles-ci

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2260336A (en) 1939-10-16 1941-10-28 Dow Chemical Co Method of preparation of organic borates
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
GB1396904A (en) * 1972-08-11 1975-06-11 Ici Ltd Method for the control of micro-organisms
US4766113A (en) 1975-10-24 1988-08-23 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4602011A (en) 1975-10-24 1986-07-22 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4716035A (en) 1985-05-24 1987-12-29 The Procter & Gamble Company Oral compositions and methods for treating gingivitis
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5348947A (en) 1993-05-07 1994-09-20 American Cyanamid Company Diarylboron ester and thioester fungicidal agents
US5348948A (en) 1993-05-07 1994-09-20 American Cyanamid Company 2,2-diaryl-1-(oxa and thia)-2a-azonia-2-borataacenaphthene fungicidal
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US5688258A (en) 1995-05-02 1997-11-18 The Procter & Gamble Company Disposable cover for an absorbent materials
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
GB9500856D0 (en) * 1995-01-17 1995-03-08 Zeneca Ltd Composition and use
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US6766183B2 (en) 1995-11-22 2004-07-20 Medtronic Minimed, Inc. Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
CA2258728C (fr) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Composes azabicycliques substitues et leur utilisation en tant qu'inhibiteurs de la production de tnf et de la photodiesterase cyclique d'amp
US5831046A (en) 1996-08-05 1998-11-03 Prolinx, Incorporated Boronic acid-contaning nucleic acid monomers
US6413751B1 (en) 1996-09-19 2002-07-02 The Board Of Trustees Of The Leland Stanford Jr. University DNA adenine methyltransferases and uses thereof
WO1998024753A1 (fr) 1996-12-02 1998-06-11 Chisso Corporation Derives de nitro-alcool actifs optiquement, derives d'amino-alcool actifs optiquement et leur procede de preparation
US6221640B1 (en) 1997-05-14 2001-04-24 Cubist Pharmaceuticals, Inc. Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
DE19829947A1 (de) 1998-07-04 2000-01-05 Bayer Ag Elektrolumineszierende Anordnungen mit Bor-Chelaten
CZ20011563A3 (cs) 1998-11-06 2003-02-12 Basf Aktiengesellschaft Tricyklické pyrazolové deriváty
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
WO2000044387A1 (fr) 1999-01-29 2000-08-03 Nitto Kasei Co., Ltd. Composes organobores presentant une activite de coccidiostats
EP1181291A2 (fr) 1999-05-25 2002-02-27 The Penn State Research Foundation Inhibiteurs de methyltransferase d'adn
AU775940B2 (en) 1999-08-25 2004-08-19 Ambergen, Inc. Methods for the detection, analysis and isolation of nascent proteins
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
WO2001025226A1 (fr) 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Derives de dithiolane
JP2003519189A (ja) 2000-01-06 2003-06-17 マランテック ホールディング リミテッド ライアビリティ カンパニー 多価電子活性組成物、その製造方法及び使用方法
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
WO2002006316A2 (fr) 2000-07-14 2002-01-24 Zycos, Inc. Composes en rapport avec $g(a)-msh et methodes d'utilisation
HUP0400651A2 (hu) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
AU2002239407B2 (en) 2000-11-30 2007-12-06 The Penn State Research Foundation DNA methyl transferase inhibitors
DE10110051C2 (de) 2001-03-02 2003-07-03 Clariant Gmbh Verfahren zur Herstellung von Boron- und Borinsäuren
RU2003132706A (ru) 2001-04-06 2005-04-20 Байокрист Фармасьютикалз, Инк. (Us) Диариловые соединения в качестве ингибиторов сериновых протеаз
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
DE10143979A1 (de) 2001-09-07 2003-03-27 Clariant Gmbh Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren
US7217701B2 (en) 2001-10-11 2007-05-15 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
JP4138662B2 (ja) 2002-01-10 2008-08-27 ザ・ペンシルバニア・ステイト・リサーチ・フアウンデイシヨン アルキルジアリールボリネートおよび錯化ジアリールボロン酸を調製するための方法。
CA2491474A1 (fr) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Polytherapie a base de composes de boroproline
WO2004043925A2 (fr) 2002-11-08 2004-05-27 Neurogen Corporation 6-aryl pyridines substituees en 3
ES2283867T3 (es) 2002-12-02 2007-11-01 Solvias Ag Hidrogenacion catalitica de dobles enlaces de carbonoheteroatomo.
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
CN101928295A (zh) 2002-12-18 2010-12-29 安那卡药品公司 含有烃基硼酸络合物的抗生素和使用方法
JP2006520397A (ja) 2003-03-14 2006-09-07 アストラゼネカ アクチボラグ 新規融合トリアゾロン類及びその使用
US20050125852A1 (en) 2003-05-09 2005-06-09 Sugen, Inc. Novel kinases
BRPI0411582A (pt) 2003-06-16 2006-08-08 Anacor Pharmaceuticals Inc substáncias terapêuticas contendo boro hidroliticamente resistentes e método de uso
JP2005022986A (ja) * 2003-06-30 2005-01-27 Sankyo Co Ltd Ｅｄｇ受容体拮抗作用を有するアルキン誘導体
NZ544244A (en) 2003-07-03 2008-10-31 Hoffmann La Roche Dual NK1/NK3 antagonists for treating schizophrenia
AU2004312510A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
KR101314461B1 (ko) 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
AR049915A1 (es) 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
KR100624238B1 (ko) 2004-06-22 2006-09-19 한국화학연구원 알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물
WO2006062731A1 (fr) 2004-11-19 2006-06-15 University Of North Texas Health Science Center At Fort Worth Utilisation de la phenanthroline et de ses derives pour abaisser la tension intraoculaire d'un oeil affecte
GB0501944D0 (en) 2005-01-31 2005-03-09 Univ Cambridge Tech Compounds for use in chemical detection and/or quantitation
ES2540966T3 (es) * 2005-02-16 2015-07-15 Anacor Pharmaceuticals, Inc. Compuestos biocidas de boronoftalida
JP5084717B2 (ja) 2005-03-08 2012-11-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ キラル・ビスオキサゾリン触媒
PE20061303A1 (es) 2005-03-30 2006-12-07 Astion Dev As Composicion farmaceutica que comprende oxaprozina
US20080234229A1 (en) 2005-08-18 2008-09-25 Auspex Pharmaceuticals, Inc. Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders
BRPI0621279B1 (pt) * 2005-12-30 2021-07-20 Anacor Pharmaceuticals, Inc Moléculas pequenas contendo boro
DK2719388T3 (da) 2006-02-16 2019-05-13 Anacor Pharmaceuticals Inc Borholdige små molekyler som antiinflammatoriske midler
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
KR20090029797A (ko) 2006-06-12 2009-03-23 아나코르 파마슈티칼스 인코포레이티드 치주질환의 치료를 위한 화합물
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
KR100895300B1 (ko) 2007-07-20 2009-05-07 한국전자통신연구원 생체신호 측정의복과 생체신호 처리시스템
EP3246034A1 (fr) 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore en tant qu'agents anti-inflammatoires
EP2187893A4 (fr) 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc Petites molécules contenant du bore utilisées en tant qu'agents anti-inflammatoires
EP2285384A4 (fr) 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc Petites molécules contenant du bore
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US9493489B2 (en) 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
WO2010045505A1 (fr) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Petites molécules contenant du bore en tant qu’agents antiprotozoaires
AR088668A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
AR088669A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos

Also Published As

Publication number Publication date
KR101426220B1 (ko) 2014-08-05
US20160108063A1 (en) 2016-04-21
US8440642B2 (en) 2013-05-14
JP6046876B2 (ja) 2016-12-21
AU2006214247C1 (en) 2012-11-08
KR20100105869A (ko) 2010-09-30
US8889656B2 (en) 2014-11-18
AU2006214247A1 (en) 2006-08-24
HK1109735A1 (en) 2008-06-20
EP1853251A2 (fr) 2007-11-14
PL2987796T3 (pl) 2018-12-31
AU2010203096B2 (en) 2010-12-02
HUE026021T2 (en) 2016-05-30
EP3424932A1 (fr) 2019-01-09
US20190330245A1 (en) 2019-10-31
PL2343304T3 (pl) 2015-09-30
AU2010203096C1 (en) 2012-09-20
BRPI0608431B8 (pt) 2021-05-25
IL185080A0 (en) 2008-08-07
EP2343304A1 (fr) 2011-07-13
US20150065459A1 (en) 2015-03-05
JP2008535781A (ja) 2008-09-04
EP1853251B1 (fr) 2013-04-24
KR20130095330A (ko) 2013-08-27
US20130244980A1 (en) 2013-09-19
JP5038912B2 (ja) 2012-10-03
SI2343304T1 (sl) 2015-08-31
HK1221956A1 (zh) 2017-06-16
RU2010133524A (ru) 2012-02-20
KR101337045B1 (ko) 2013-12-05
WO2006089067A2 (fr) 2006-08-24
EP2343304B1 (fr) 2015-06-10
NL301049I1 (nl) 2020-07-01
EP2987796B1 (fr) 2018-08-08
HUE054365T2 (hu) 2021-09-28
CA2597982A1 (fr) 2006-08-24
CN101160124A (zh) 2008-04-09
KR20130100019A (ko) 2013-09-06
US20170066788A1 (en) 2017-03-09
RU2016145916A (ru) 2018-05-23
PT3424932T (pt) 2021-05-19
DK2343304T3 (en) 2015-06-29
ZA200707408B (en) 2009-11-25
EP3424932B1 (fr) 2021-04-07
IL207156A (en) 2014-04-30
US8039451B2 (en) 2011-10-18
NZ560448A (en) 2009-08-28
BRPI0608431B1 (pt) 2020-09-15
US20190048026A1 (en) 2019-02-14
AU2010203096A1 (en) 2010-08-12
RU2414906C2 (ru) 2011-03-27
US7582621B2 (en) 2009-09-01
EP1853251A4 (fr) 2010-01-13
HUS2000019I1 (hu) 2020-07-28
NZ578297A (en) 2010-11-26
LTPA2020524I1 (lt) 2020-09-10
US20060234981A1 (en) 2006-10-19
PT2987796T (pt) 2018-10-18
ES2686981T3 (es) 2018-10-23
PL3424932T3 (pl) 2021-09-20
CA2597982C (fr) 2014-07-08
RU2007134429A (ru) 2009-03-27
HK1160139A1 (en) 2012-08-10
NL301049I2 (nl) 2020-09-10
WO2006089067A3 (fr) 2007-07-19
FR20C1024I2 (fr) 2021-07-09
ZA201506944B (en) 2018-08-29
RU2016145916A3 (fr) 2020-07-21
CY2020027I2 (el) 2021-01-27
JP2010248265A (ja) 2010-11-04
RU2606947C2 (ru) 2017-01-10
CN101914109B (zh) 2014-07-23
JP2016020374A (ja) 2016-02-04
CY1124503T1 (el) 2022-07-22
SI2987796T1 (sl) 2018-11-30
US20140142064A1 (en) 2014-05-22
ZA201005380B (en) 2016-08-31
IL185080A (en) 2012-07-31
PL1853251T3 (pl) 2013-09-30
AU2006214247B2 (en) 2010-08-05
CY1120695T1 (el) 2019-12-11
KR101337068B1 (ko) 2013-12-06
AU2011200994A1 (en) 2011-03-31
KR101456815B1 (ko) 2014-10-31
EP2987796A1 (fr) 2016-02-24
SI3424932T1 (sl) 2021-08-31
FR20C1024I1 (fr) 2020-07-31
ES2414095T3 (es) 2013-07-18
DK3424932T3 (da) 2021-05-25
DK2987796T3 (en) 2018-09-17
KR20070112390A (ko) 2007-11-23
JP2017105826A (ja) 2017-06-15
JP2013018778A (ja) 2013-01-31
US20100190748A1 (en) 2010-07-29
US20110319361A1 (en) 2011-12-29
PT1853251E (pt) 2013-07-19
ZA200905950B (en) 2010-11-24
HUE040060T2 (hu) 2019-02-28
CY2020027I1 (el) 2021-01-27
LUC00157I1 (fr) 2020-06-08
NZ598441A (en) 2013-07-26
US20210070780A1 (en) 2021-03-11
LTC2343304I2 (lt) 2022-11-10
JP2014132031A (ja) 2014-07-17
ES2872962T3 (es) 2021-11-03
ES2540966T3 (es) 2015-07-15
CN101914109A (zh) 2010-12-15
MX369262B (es) 2019-11-04
PT2343304E (pt) 2015-08-26
BRPI0608431A2 (pt) 2009-12-29

Similar Documents

Publication Publication Date Title
FR20C1024I1 (fr)
BRPI0601358B8 (pt) Aplicador de clipe cirúrgico
BRPI0601402B8 (pt) Aplicador de grampos cirúrgicos
BR122017004709A2 (fr)
BRPI0609157A8 (fr)
BRPI0608519A2 (fr)
BR122020005056A2 (fr)
AP2140A (fr)
BR122016029989A2 (fr)
BRPI0604219A (fr)
JP2006216772A5 (fr)
JP2006326795A5 (fr)
BRPI0618215B8 (fr)
JP2005320969A5 (fr)
JP2007033052A5 (fr)
BY2237U (fr)
JP2006254340A5 (fr)
JP2006190421A5 (fr)
CN105122969C (fr)
CN300756849S (zh) 开关
CN300726699S (zh) 调料瓶套装(d)
CN300756858S (zh) 开关
CN300726222S (zh) 包装纸(金色高金火腿肠)
CN300726696S (zh) 调料瓶套装(c)
CN300725991S (zh) 鞋帮